Quantcast
Home > Quotes > RXII
RXII

RXi Pharmaceuticals Corporation Common Stock (RXII) Quote & Summary Data

$0.3313
*  
0.0013
0.39%
Get RXII Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading RXII now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
2
Today's High / Low
$ 0.332 / $ 0.32
Share Volume
460,824
50 Day Avg. Daily Volume
1,605,989
Previous Close
$ 0.33
52 Week High / Low
$ 7.70 / $ 0.31
Market Cap
2,692,049
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.27

Intraday Chart

Shares Traded

Share Volume:
460,824
50 Day Avg. Daily Volume:
1,605,989

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.54

Trading Range

The current last sale of $0.3313 is 6.87% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.332 $ 7.70
 Low: $ 0.32 $ 0.31

Company Description (as filed with the SEC)

RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering and developing immuno-oncology therapeutics to treat cancer based on our self-delivering RNAi ("sd-rxRNA®") platform. Our sd-rxRNA compounds do not require a delivery vehicle to penetrate the cell and are designed to "silence," or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. This provides RXi with a distinct advantage in adoptive cell therapy, the Company's initial focus and approach to immuno-oncology. Prior to our acquisition of MirImmune Inc. ("MirImmune") in January 2017, the Company's principal activities consisted of the preclinical and clinical development of our sd-rxRNA compounds and topical immunotherapy agent in the areas of dermatology and ophthalmology.  ... More ...  


Risk Grade

Where does RXII fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.33
Open Date:
Nov. 16, 2018
Close Price:
$ 0.335
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x